- cafead Mar 21, 2024 at 11:42: AM
via Having some free time following the $10.8 billion buyout of Prometheus Biosciences made Mark McKenna realize he had some “unfinished business.”
Prometheus had managed to create a therapeutic that improved efficacy in inflammatory bowel disease from about 15% to over 25%. But what about the other 75%?
article source
Prometheus had managed to create a therapeutic that improved efficacy in inflammatory bowel disease from about 15% to over 25%. But what about the other 75%?
article source